Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Published:2019-10 Issue:10 Volume:20 Page:1370-1385
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Motzer Robert J,Rini Brian I,McDermott David F,Arén Frontera Osvaldo,Hammers Hans J,Carducci Michael A,Salman Pamela,Escudier Bernard,Beuselinck Benoit,Amin Asim,Porta Camillo,George Saby,Neiman Victoria,Bracarda Sergio,Tykodi Scott S,Barthélémy Philippe,Leibowitz-Amit Raya,Plimack Elizabeth R,Oosting Sjoukje F,Redman Bruce,Melichar Bohuslav,Powles Thomas,Nathan Paul,Oudard Stéphane,Pook David,Choueiri Toni K,Donskov Frede,Grimm Marc-Oliver,Gurney Howard,Heng Daniel Y C,Kollmannsberger Christian K,Harrison Michael R,Tomita Yoshihiko,Duran Ignacio,Grünwald Viktor,McHenry M Brent,Mekan Sabeen,Tannir Nizar M

Funder

Memorial Sloan Kettering

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

2. OPDIVO (nivolumab),2018

3. YERVOY (ipilimumab),2018

4. Updates to the management of kidney cancer;Jonasch;J Natl Compr Canc Netw,2018

5. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial;Cella;Lancet Oncol,2019

Cited by 622 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety;Urologic Oncology: Seminars and Original Investigations;2024-11

2. Effect of Treatment of Residual Disease After Immunotherapy-Based Combinations on Complete Response Rate of Patients With Metastatic Renal Cell Carcinomas;Clinical Genitourinary Cancer;2024-10

3. External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma;Frontiers in Oncology;2024-09-02

4. Preliminary Research of Radiolabeled Atezolizumab for the Noninvasive Evaluation of TNBC PD‐L1 Expression In Vivo;Journal of Labelled Compounds and Radiopharmaceuticals;2024-08-30

5. Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report;Immunotherapy;2024-08-19